<DOC>
	<DOC>NCT00751556</DOC>
	<brief_summary>To determine the pharmacokinetic profile of an extended release tablet of naproxen sodium 660 mg relative to the established commercial Aleve 220 mg tablet following single dose administration and at steady-state following multiple dose administration for 4 days.</brief_summary>
	<brief_title>Single/Multiple Dose Bioavailability Trial</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy, ambulatory, male and female volunteers between 18 55 years of age with BMI of approximately 18 to 30 kg/m2, and total body weight &gt;50 kg (110Ibs) History of hypersensitive to aspirin (ASA), naproxen sodium, or acetaminophen, and similar pharmacological agents or components of the products History of gastrointestinal bleeding or perforation related to previous NonSteroidal AntiInflammatory Drug (NSAID) therapy Active, or history of current peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding) Have taken ASA, ASAcontaining products, acetaminophen (acetylparaaminophenol or APAP) or any other NSAID (OTC or prescription) 7 days prior to dosing or during the treatment period, other than study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Naproxen Sodium</keyword>
	<keyword>Bioavailability</keyword>
</DOC>